More Stories

Informist, Friday, Oct. 24, 2025

MUMBAI – The Nifty Pharma sectoral index is likely to be range-bound next week owing to the lack of fresh triggers, but stock-specific reactions are possible based on their September quarter earnings, according to analysts. The financial results of Dr. Reddy's Laboratories and Cipla might be stepping stones to gauge the growth of the Indian pharmaceutical market.

Dr. Reddy's reported slightly lower-than-expected consolidated net profit of INR 13.47 billion for the September quarter, but its revenue from operations was INR 88.28 billion, surpassing analysts' expectations of INR 87 billion. Price erosion in some products in the US and lower sales of the cancer drug generic Revlimid were key reasons for the net profit being below analysts' estimate. Sales from North America, which account for nearly 40% of the company's consolidated revenue, declined 13% on year to INR 32.41 billion.

Cipla will report its September quarter earnings Thursday. The company is expected to report a 7% year-on-year rise in consolidated net profit to INR 13.97 billion. Analysts said the company is likely to report a robust set of numbers despite erosion of its market share and pricing pressure in the US, thanks to growth in the domestic market and in other countries. The company has signed a distribution and promotion agreement with Eli Lilly for tirzepatide, under a second brand named Yurpeak, in India. Brokerages are bullish on Cipla's growth in the long term as this deal will give the company early access to an effective and fast-growing glucagon-like peptide-1 drug.

The Nifty Pharma index is expected to move in a broader range of 22000-22500 points, according to Anshul Jain, technical analyst at Laxmishree Securities and Investments. For the week ended Friday, the index ended 0.5% lower at 22357.35 points with Glenmark Pharmaceuticals being the worst-performing stock in the index, falling over 2%. Piramal Pharma and Laurus Labs were the biggest gainers, rising 5% and 3%, respectively.

TOP HEADLINES

* Analyst Concall: Dr Reddy's to partner with US contract mfg co for abatacept
* Earnings Review: Dr Reddy's Jul-Sept consol PAT rises 7% YoY but misses view
* Lupin launches Ravicti generic in US for managing urea cycle disorders
* Syngene Intl to expand biologics facility with new antibody-drug conjugates
* Caplin Point arm gets US FDA approval for hypertension drug nicardipine
* Cipla to sell Eli Lilly's Mounjaro under brand name Yurpeak
* Laurus Labs consol PAT surges manifold YoY in Jul-Sept, revenue jumps 35%
* Earnings Outlook: India ops to aid Cipla's Q2 show, margins under pressure
* Torrent Pharma gets CCI's approval to buy controlling stake in JB Chemicals
* Glenmark Pharma US arm to launch Ropivacaine Hydrochloride injection in Nov
* Biocon arm gets Health Canada's nod for Stelara, Stelara IV biosimilars
* IPO Alert: Sudeep Pharma gets SEBI approval for fresh issue, OFS
* US FDA tags Dr Reddy's mfg unit in Andhra 'voluntary action indicated'
* Alembic Pharma gets US FDA final OK for triamcinolone acetonide injectable
* Crisil revises Emcure Pharma's long-term rtg outlook to positive from stable
* Ipca Lab to sell its drug, API mfg unit in Gujarat to Suleshvari Pharma

Following are the resistance and support levels for key pharmaceutical stocks for next week, as per calculations based on their prices on the National Stock Exchange:

End

Reported by P. Madhu Kumar

Edited by Rajeev Pai

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

© Informist Media Pvt. Ltd. 2025. All rights reserved.